A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Clinical trial NCT01998971 · COMPLETED
Trial details
- NCT number
- NCT01998971
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-18
- Primary completion
- 2019-01-31
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.